Fibrogen announces completion of patient enrollment in zephyrus-2, a phase 3 clinical study of pamrevlumab in idiopathic pulmonary fibrosis

- 372 ipf patients enrolled - - topline data anticipated mid-2024 -
FGEN Ratings Summary
FGEN Quant Ranking